Association of High LAT1 Expression with Poor Prognosis and Recurrence in Colorectal Cancer Patients Treated with Oxaliplatin-Based Adjuvant Chemotherapy

被引:6
|
作者
Shibasaki, Yuta [1 ]
Yokobori, Takehiko [2 ]
Sohda, Makoto [1 ]
Shioi, Ikuma [1 ]
Ozawa, Naoya [1 ]
Komine, Chika [1 ]
Suga, Kunihiko [1 ]
Nakazawa, Nobuhiro [1 ]
Osone, Katsuya [1 ]
Shiraishi, Takuya [1 ]
Okada, Takuhisa [1 ]
Sano, Akihiko [1 ]
Sakai, Makoto [1 ]
Ogawa, Hiroomi [1 ]
Kaira, Kyoichi [3 ]
Shirabe, Ken [1 ]
Saeki, Hiroshi [1 ]
机构
[1] Gunma Univ, Grad Sch Med, Dept Gen Surg Sci, Maebashi 3718510, Japan
[2] Gunma Univ Initiat Adv Res GIAR, Div Integrated Oncol Res, Maebashi 3718511, Japan
[3] Saitama Univ Hosp, Comprehens Canc Ctr, Int Med Ctr, Dept Resp Med, Hidaka 3501298, Japan
基金
日本学术振兴会;
关键词
L-type amino acid transporter-1; cancer aggressiveness; prognostic marker; chemosensitivity marker; TRANSPORTER; FLUOROURACIL; LEUCOVORIN; LEVAMISOLE; RESISTANCE; THERAPY; ASCT2;
D O I
10.3390/ijms24032604
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The mammalian target of rapamycin (mTOR) is often activated in several cancers. We focused on two mTOR regulatory mechanisms: oxaliplatin-induced mTOR signaling and L-type amino acid transporter 1 (LAT1)-induced mTOR activation. High LAT1 expression in several cancers is associated with mTOR activation and resistance to chemotherapy. However, the significance of LAT1 has not yet been elucidated in colorectal cancer (CRC) patients treated with post-operative adjuvant chemotherapy. Immunohistochemistry was conducted to examine the significance of membrane LAT1 expression in 98 CRC patients who received adjuvant chemotherapy, including oxaliplatin. In vitro analysis was performed using CRC cell lines to determine the effects of LAT1 suppression on proliferation, oxaliplatin sensitivity, and mTOR signaling. LAT1 expression was associated with cancer aggressiveness and poor prognosis in 98 CRC patients treated with adjuvant chemotherapy. We found that positive LAT1 expression correlated with shorter survival in 43 patients treated with the capecitabine-plus-oxaliplatin (CAPOX) regimen. LAT1 suppression in CRC cells inhibited the proliferation potency and oxaliplatin-induced activation of mTOR signaling, and improved oxaliplatin sensitivity. LAT1 evaluation before adjuvant treatment may therefore be a sensitive marker for oxaliplatin-based regimens. Moreover, LAT1 may be a promising target for patients with refractory CRC.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases
    Giannini, Valentina
    Pusceddu, Laura
    Defeudis, Arianna
    Nicoletti, Giulia
    Cappello, Giovanni
    Mazzetti, Simone
    Sartore-Bianchi, Andrea
    Siena, Salvatore
    Vanzulli, Angelo
    Rizzetto, Francesco
    Fenocchio, Elisabetta
    Lazzari, Luca
    Bardelli, Alberto
    Marsoni, Silvia
    Regge, Daniele
    CANCERS, 2022, 14 (01)
  • [42] Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study)
    Kotaka, Masahito
    Iwamoto, Shigeyoshi
    Satake, Hironaga
    Sakai, Daisuke
    Kudo, Toshihiro
    Fukunaga, Mutsumi
    Konishi, Ken
    Ide, Yoshihito
    Ikumoto, Taro
    Tsuji, Akihito
    Sano, Yasushi
    Kato, Takeshi
    Sugimoto, Naotoshi
    Satoh, Taroh
    Kanazawa, Akiyoshi
    Kurata, Takayasu
    Yamanaka, Takeharu
    Tomita, Naohiro
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2020, 25 (08) : 1515 - 1522
  • [43] Bevacizumab Plus Irinotecan-Based Therapy in Metastatic Colorectal Cancer Patients Previously Treated With Oxaliplatin-Based Regimens
    Yildiz, Ramazan
    Buyukberber, Suleyman
    Uner, Aytug
    Yamac, Deniz
    Coskun, Ugur
    Kaya, Ali Osman
    Ozturk, Banu
    Yaman, Emel
    Benekli, Mustafa
    CANCER INVESTIGATION, 2010, 28 (01) : 33 - 37
  • [44] ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy
    Li, P.
    Fang, Y. J.
    Li, F.
    Ou, Q. J.
    Chen, G.
    Ma, G.
    BRITISH JOURNAL OF CANCER, 2013, 108 (06) : 1238 - 1244
  • [45] Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy
    Martinez-Balibrea, Eva
    Martinez-Cardus, Anna
    Musulen, Eva
    Gines, Alba
    Luis Manzano, Jose
    Aranda, Enrique
    Plasencia, Carmen
    Neamati, Nouri
    Abad, Albert
    INTERNATIONAL JOURNAL OF CANCER, 2009, 124 (12) : 2905 - 2910
  • [46] The bevacizumab plus oxaliplatin-based chemotherapy regimen is more suitable for metastatic colorectal cancer patients with a history of schistosomiasis: a clinical retrospective analysis
    Zhou, Li-Na
    Feng, Chun-Xia
    Zhang, Yan
    Li, Ping
    Tang, Min
    Chen, Min-Bin
    Jin, Jun
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2022, 13 (03) : 1086 - 1096
  • [47] Diabetes and Body Mass Index Are Associated with Neuropathy and Prognosis in Colon Cancer Patients Treated with Capecitabine and Oxaliplatin Adjuvant Chemotherapy
    Ottaiano, Alessandro
    Nappi, Anna
    Tafuto, Salvatore
    Nasti, Guglielmo
    De Divitiis, Chiara
    Romano, Carmela
    Cassata, Antonino
    Casaretti, Rossana
    Silvestro, Lucrezia
    Avallone, Antonio
    Capuozzo, Maurizio
    Capozzi, Monica
    Maiolino, Piera
    Quagliariello, Vincenzo
    Scala, Stefania
    Iaffaioli, Vincenzo Rosario
    ONCOLOGY, 2016, 90 (01) : 36 - 42
  • [48] Association of XPD Asp312Asn polymorphism and response to oxaliplatin-based first-line chemotherapy and survival in patients with metastatic colorectal cancer
    Liu, Zhuo
    Kong, Jiangyin
    Kong, Yuanyuan
    Cai, Feng
    Xu, Xiaocheng
    Liu, Jun
    Wang, Shihua
    ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 28 (11): : 1459 - 1468
  • [49] ERCC5 promoter polymorphisms at-763 and+25 predict the response to oxaliplatin-based chemotherapy in patients with advanced colorectal cancer
    Chen, Jianfang
    Xie, Fangwei
    Chen, Keli
    Wang, Dong
    Jiang, Heng
    Li, Jianjun
    Pan, Feng
    Chen, Shixu
    Zhang, Yanling
    Ruan, Zhihua
    Huang, Haihui
    Zou, Lan
    Liang, Houjie
    CANCER BIOLOGY & THERAPY, 2009, 8 (14) : 1424 - 1430
  • [50] K-Ras gene mutation status as a prognostic and predictive factor in patients with colorectal cancer undergoing irinotecan- or oxaliplatin-based chemotherapy
    Stec, Rafal
    Bodnar, Lubomir
    Charkiewicz, Radoslaw
    Korniluk, Jan
    Rokita, Marta
    Smoter, Marta
    Ciechowicz, Marzena
    Chyczewski, Lech
    Niklinski, Jacek
    Kozlowski, Wojciech
    Szczylik, Cezary
    CANCER BIOLOGY & THERAPY, 2012, 13 (13) : 1235 - 1243